DKK1 Positively Correlates with Lung Function in COPD Patients and Reduces Airway Inflammation

Abstract

Purpose

WNT/β-catenin signal pathway is a potential hope for lung tissue repair. We investigated the levels of Dickkopf‐1 (DKK1), an endogenous inhibitor of WNT/β-catenin signal pathway, in chronic obstructive pulmonary disease (COPD) patients and airway inflammation.

Patients and Methods

Collected the demographic and clinical characteristics of 36 healthy controls, 25 stable COPD patients and 10 acute exacerbation of COPD (AECOPD) patients, then performed pulmonary function and detected serum DKK1 levels. After over-expression of DKK1, detect the levels of DDK1, lipoprotein-related protein 6 (LRP6) and inflammatory factors in bronchial epithelial cells stimulated with cigarette smoke extract (CSE).

Results

Serum DKK1 were reduced in stable COPD patients compared to healthy controls (3866.72 ± 775.33 pg/mL vs 5317.61 ± 1317.20 pg/mL, p<0.0001), but there was no significant difference between stable and acutely exacerbated patients (3866.72 ± 775.33 pg/mL vs 3482.10 ± 841.25 pg/mL, p>0.05). DKK1 was positively correlated with FEV1 (r = 0.570, p<0.0001), FEV1/FVC (rho = 0.590, p<0.0001), FEV1/Pre (r = 0.517, p<0.0001). Multiple linear regression analysis also suggested that FEV1 levels were higher with increasing DKK1. In vitro, elevated IL-6, IL-8, TNF-α and decreased DKK1, LRP6 were found in Beas-2B cells after CSE treatments, and increased LRP6 and decreased inflammatory factors were found after overexpression of DKK1. Andrographolide restored the CSE-induced decrease in DKK1 and increase in IL-6 and IL-8.

Conclusion

DKK1 levels were decreased in COPD patients and positively correlated with lung function, overexpression of DKK1 and andrographolide attenuated airway cell inflammation, both suggesting a potential role in pathophysiology and providing a disease-specific biomarker pattern.

Keywords:

• LRP6
• lung function
• biomarker
• andrographolide

Introduction

Dickkopf-1 (DKK1) a secretory glycoprotein, is an important member of DKK protein family. It was first discovered by Glinka and his colleagues in the embryonic cells of Xenopus in 1998.¹ DKK protein family is an ancient and evolutionarily conserved gene family, which consists of 255–350 amino acid residues, including a signal peptide sequence and two conserved cysteine rich regions.^2–4 The abnormal expression of DKK1 can affect the expression of certain proteins and genes in many signaling pathways. At present, the research on DKK1 focuses on the background of canonical WNT/β-catenin signaling pathway, and DKK1 is recognized as a well-established inhibitor of β-catenin-dependent WNT signal. The C-terminal cysteine rich region of DKK1 can bind with low density lipoprotein-related protein 6 (LRP6) and kremen2, then blocking WNT signaling pathway.^5–7

The WNT signaling pathway, which is active during the normal development of the lung, its abnormal activation is involved in the development of many chronic lung diseases including chronic obstructive pulmonary disease (COPD).^8–10 Previous studies have found that WNT/β-catenin signaling pathway activity at the lung tissue of COPD patients is reduced, while activation of this pathway can reduce cigarette smoke-induced lung inflammation and elastase-induced emphysema in mice.^11–13 Studies have shown that circulating levels of DKK1 are associated with a variety of inflammatory diseases such as osteoarthritis, rheumatoid arthritis, periodontitis, and acute infections.^14,15 As for the lung, DKK1 is involved in regulating WNT-induced epithelial cell proliferation in a dose-dependent manner.¹⁶ Mice lung inflammation is relieved after intratracheal administration of Wnt3a or antibodies neutralizing DKK1.¹⁷

The above studies suggest that DKK1 may play a role in chronic inflammation in COPD, and in this study, we measured DKK1 in the blood circulation of COPD patients and healthy controls, then further explored the relationship between DKK1 levels and lung function.

Materials and Methods

Patient Inclusion

The research protocol followed the principles of the Declaration of Helsinki and was approved by the Institutional Review Board for Human Studies of West China Hospital of Sichuan University, China (Approved No. of ethic committee:2017(270)). During the period from January to October 2016 to December 2018, we randomly recruited healthy subjects, stable COPD patients and AECOPD patients from the outpatient and inpatient departments of West China Hospital. All subjects signed written informed consent. Pulmonary function in COPD patients met the diagnostic criteria of Global Strategy for the Diagnosis, Management, and Prevention of COPD (updated 2015). Based on the value of FEV1/FVC, COPD patients can be divided into 4 grades: GOLD stage I, ≥80%; GOLD stage II, ≥50% to <80%; GOLD stage III, ≥30% to <50%; and GOLD stage IV, <30% predicted). Subjects with lung-related disease (lung cancer, asthma, etc.), severe systemic disease, or medical history known to affect circulating DKK1 (including osteoarthritis, rheumatoid arthritis, acute infection and many other diseases) were excluded.^14,15

Collection of the Basic Information

Information such as name, gender, ethnicity, age, height, weight, smoking history, symptoms, and lung function data of included subjects were collected. All subjects were tested for pulmonary function by a professional.

Blood Collection and Assays

All subjects were required to fast from 9 pm the night before; the venous blood samples were collected the next morning, 1 hour later, centrifuged at 3000 rpm for 10 minutes to separate the serum, and stored at −80°C until analysis. DKK1, TNF-α, and IL-6 were measured using Magnetic Luminex Screening Assay (R&D Systems, Minneapolis, MN, USA) in the laboratory of West China Hospital.

Cell Culture and Transfection

The bronchial epithelial cell line BEAS-2B was purchased from ATCC and cultured in DMEM (Gibco Life Technologies) containing 10% fetal bovine serum (Gemini, 900–108) and 1% penicillin and streptomycin, cigarette smoke extract was obtained from commercial cigarettes (Marlboro, Phillips Morris, Richmond, VA, USA; 1.0 mg nicotine and 11 mg tar per cigarette), CD513B-1 and pCD513B-1-DKK1 plasmids were purchased from PPL (Nanjing, China), lipofectamine 3000 (Invitrogen Life Technologies) was used to transfect the plasmid into BEAS-2B cells.

Western Blotting and ELISA Assay

RIPA lysis buffer, protease inhibitor cocktail (beyotime, China) and PMSF (Cell Signaling Technology, Danvers, MA, USA) were added to the cells. After complete lysis, centrifuged at 12000g for 30 minutes. The obtained protein was denatured with SDS loading buffer. Protein was fractionated by SDS polyacrylamide gel electrophoresis and incubated overnight at with antibodies against DKK1 (Affinity, China), GAPDH (ZENBIO, China), LRP6 (Cell Signaling Technology), respectively. After washing several times with TBST, the membranes were incubated with a secondary antibody. Collect the cell supernatant and use enzyme-linked immunosorbent assay (USA R&D Systems) to detect IL-6, IL-8 and TNF-α according to the manufacturer’s instructions.

Statistical Analysis

All the data were analyzed by SPSS 22.0 for windows (IBM, Chicago, IL), and graphs were drawn with GraphPad Prism 6.01 for Windows (GraphPad Software Inc, La Jolla, CA, USA). Shapiro–Wilk test was used to determine whether quantitative data follow a normal distribution. If the data satisfied normal distribution, independent samples t test, chi-square test and one-way ANOVA were used to compare differences between groups. Pearson’s correlation coefficient and Spearman’s rho were used to determine the correlation between DKK1 and lung function parameters in normal and non-normal data, respectively. All data were expressed as mean ± standard deviation (SD). Bilateral p< 0.05 was considered statistically significant.

Results

COPD patients were defined as FEV 1: FVC ratio less than 0.7 after using bronchodilators. Our study ultimately included 71 subjects, including 36 controls, 25 patients with stable COPD, 10 patients with AECOPD. The baseline data are shown in Table 1. FVC (2.39 ± 0.74 L vs 3.49 ± 0.65 L), FEV1 (1.23 ± 0.52 L vs 3.14 ± 0.62 L), FEV1/FVC (51.13 ± 12.12% vs 90.36 ± 8.24%), FEV1/Pre (51.28 ± 19.14% vs 103.75 ± 14.57%) in stable COPD patients were significantly lower than those in the control group and this decrease was also observed in AECOPD patients (p < 0.0001). There was no significant difference in lung function between stable COPD and AECOPD patients (p > 0.05).

Table 1 Characteristics of Healthy Controls, Stable COPD and AECOPD Patients

Characteristics	Healthy Controls (n=36)	Stable COPD Patients (n=25)	AECOPD Patients (n=10)	P-value
Age, years	48.44 ± 7.92	64.20 ± 8.09	71.50 ± 8.34	< 0.0001*
Sex, male/female	32/4	20/5	9/1	0.570
BMI, kg/m^2	22.13 ± 2.67	23.26 ± 3.29	22.01 ± 2.66	0.281
Smoking history, Never-smoker/smoker,	22/14	7/18	1/9	0.003*
FVC, L	3.49 ± 0.65	2.39 ± 0.74	2.05 ± 0.69	< 0.0001*
FEV1, L	3.14 ± 0.62	1.23 ± 0.52	1.03 ± 0.50	< 0.0001*
FEV1/FVC, %	90.36 ± 8.24	51.13 ± 12.12	48.56 ± 11.34	< 0.0001*
FEV1/Pre, %	103.75 ± 14.57	51.28 ± 19.14	47.90 ± 28.19	< 0.0001*
DKK1, pg/mL	5317.61 ± 1317.20	3866.72 ± 775.33	3482.10± 841.25	< 0.0001*

Note: *p<0.05, the result is statistically significant.

DKK1 Decreased Significantly in COPD Patients

Compared with controls, serum DKK1 levels in patients with stable COPD and AECOPD were significantly reduced (5317.61 ± 1317.20 pg/mL vs 3866.72 ± 775.33 pg/mL, 3482.10 ± 841.25 pg/mL, p <0.05, Figure 1A). Since there were only 10 AECOPD patients, and the differences in baseline information and DKK1 levels between the two subgroups of COPD patients were not statistically significant, we performed a combined analysis. The results showed no significant difference in DKK1 levels between the smoking and nonsmoking groups (p > 0.05, Figure 1B). Similarly, due to the small sample size, individuals with GOLD stage I and II, individuals with GOLD stage III and IV, were combined respectively. GOLD stage III–IV patients serum showed greatest decrease in DKK1 compared to that of GOLD stage I–II patients and healthy subjects (3428.88 ± 726.46 pg/mL vs 4066.56 ± 761.36 pg/mL, 5317.61 ± 1317.20 pg/mL, p<0.05, Figure 1C).

Figure 1 Levels of DKK1 in serum.

Notes: (A) The DKK1 levels in stable COPD (n=25) and AECOPD patients (n=10) were significantly lower than those in healthy subjects (n=36). (B) No statistical difference between smokers and nonsmokers in healthy subjects or in COPD patients. (C) GOLD stage III–IV patient serum showed greatest decrease in DKK1 compared to that of healthy subjects and GOLD stage I–II patients. DKK1, Dickkopf‐1; GOLD=Global Initiative for Chronic Obstructive Lung Disease. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Correlation Between DKK1 and Lung Function

Pulmonary function test is an important method for diagnosing and evaluating COPD patients, the correlation between DKK1 and lung function was analyzed. DKK1 was positively correlated with FVC (r=0.462, p<0.0001), FEV1 (r=0.570, p<0.0001), FEV1/FVC (rho=0.590, p<0.0001), and FEV1/Pre (rho=0.517, p<0.0001, Table 2, Figure 2). After adjusting for age, gender, BMI, smoking history, the significant correlation was still observed in FEV1 (r=0.358, p=0.003), FEV1/FVC (r=0.377, p=0.002), FEV1/ Pre (r=0.346, p=0.004), but no significant correlation was found between FVC and DKK1 (r=0.229, p=0.063, Table 2).

Table 2 Correlation Between DKK1 and Lung Function

	Linear Correlation		Partial Correlation
	DKK1		DKK1
	r/rho	p	r	p
FVC	0.462	<0.0001*	0.229	0.063
FEV1	0.570	<0.0001*	0.358	0.003*
FEV1/FVC	0.590	<0.0001*	0.377	0.002*
FEV1/Pre	0.517	<0.0001*	0.346	0.004*

Note: *p<0.05, the result is statistically significant.

Figure 2 Correlation Between FVC, FEV1, FEV1/FVC, FEV1/Pre and DKK1.

Notes: DKK1 levels were found to be positively correlated with (A) FVC (r=0.462, p<0.0001), (B) FEV1 (r=0.570, p<0.0001), (C) FEV1/FVC (rho=0.590, p<0.0001), and (D) FEV1 (rho=0.517, p<0.0001). Pearson’s correlation coefficient (r) and Spearman’s rho were used to determine the correlation.

Multiple Linear Regression Analysis

In order to exclude other factors affecting DKK1, we conducted a multiple linear regression analysis of age, BMI, gender, FEV1, and FVC. The main results are shown in Table 3. The results showed no interaction between all subjects (DW=2.089). These factors were independent of each other without collinearity (VIF<10) and could explain 39.8% (R square=0.398) of the variance in DKK1. Both BMI and FEV1 significantly and positively affected the level of DKK1 (B=95.256, p=0.038, B= 775.820, p=0.016, respectively).

Table 3 Multiple Linear Regression Analysis

Parameter	R Square	Durbin-Watson	Unstandardized B	P-valve	VIF
Age	0.398	2.089	−17.807	0.293	2.485
BMI			95.256	0.038*	1.012
FVC			−250.336	0.475	6.034
FEV1			775.820	0.016*	7.550
Sex			435.982	0.354	1.586
Smoking history			179.747	0.593	1.635

Note: *p<0.05, the result is statistically significant.

DKK1 Regulates the Production of LRP6 and Inflammatory Factors in Response to CSE Exposure in BEAS-2B

Same as previous studies, CSE induced inflammation in airway epithelial cells.^18,19 Enzyme-linked immunosorbent assay (ELISA) showed that TNF-α and IL-6 were upregulated in cells treated with different concentrations of CSE, and elevated IL-8 was observed in 3% CSE and 4% CSE-treated groups (Figure 3A). 2% CSE, 3% CSE and 4% CSE decreased the protein levels of DKK1 and LRP6 (Figure 3B). When DKK1 was overexpressed, CSE-stimulated LRP6 protein increased (Figure 3C) and TNF-α levels in the cell supernatant decreased (Figure 3D), suggesting that in epithelial cells, DKK1 can act as an upstream regulator of LRP6 in response to CSE stimulation and airway inflammation can be inhibited by DKK1. Pretreatment with andrographolide resulted in increased expression of LRP6 and DKK1 (Figure 3C) and decreased levels of IL-6 and IL-8 (Figure 3D).

Figure 3 DKK1 regulated LRP6 and airway inflammation, andrographolide elevated DKK1 and LRP6 and reduced airway inflammation.

Notes: (A) Detection of TNF-α, IL-6 and IL-8 in the cell supernatant after treatment of cells with different concentrations of CSE. (B) Western blot and PCR showed changes of DKK1 and LRP6 after CSE treatment. (C) Cells were pre-transfected with DKK1 overexpression plasmid or Andrographolide, followed by treatment with CSE, Western blot was used to detect protein levels. (D) Changes in TNF-α, IL-6 and IL-8 in cell supernatants in different treatment groups. Andro: Andrographolide. *p<0.05 with, **p<0.01, ****p<0.0001, respect to the blank group, ^#p< 0.05, ^####p<0.0001, with respect to the CD513B-1+2% CSE group, ^Δp < 0.05 with respect to the 2% CSE group.

Discussion

This study is the first to explore the role of DKK1 in COPD, bringing new implications to the role of DKK1 in the WNT pathway. DKK1 is recognized as an inhibitor of the canonical WNT/β-catenin signaling pathway.^6,20,21 Platelets are the main source of circulating DKK1, and an increase in DKK1 leads to the formation of leukocyte-platelet aggregates (LPA), which facilitates leukocyte infiltration.²² In the lung, DKK1 promotes macrophage and neutrophil infiltration by inhibiting the WNT pathway, and the infiltration of inflammatory cells is alleviated after inhibition of DKK1.¹⁷ DKK1 can induce the production of IL-4, IL-10, IL-13 in CD4+ T cells and the production of Th2 cytokines, which together contribute to airway inflammation.²³ However, the relationship between DKK1 and COPD is still unclear. In this study, we compared the differences in circulating DKK1 in control subjects, patients with stable COPD and AECOPD, moreover, further analyzed the correlation between DKK1 and lung function.

We found that DKK1 levels were decreased in both the stable COPD and AECOPD groups compared to the control group. The level of DKK1 in GOLD stage III–IV patients was lower than that of GOLD stage I–II. Correlation analysis showed that DKK1 was significantly positively correlated with FVC, FEV1, FEV1/FVC, and FEV1/Pre, additional multiple linear regression confirmed that with FEV1 significantly positively affect DKK1.These findings suggest that DKK1 is positively correlated with the lung function, the better the lung function, the higher the DKK1 level. Previous studies have shown that DKK1 in patients with periodontitis, rheumatoid patients, and acute infections is higher than that in normal groups.^14,24 The increased levels of DKK1 in these inflammatory diseases are contrary to our findings, and it is clear that these results above cannot be completely explained by DKK1 being an inhibitor of canonical WNT/β-catenin pathway. Atsushi Niida et al found that DKK1 may also be involved in the activation of the WNT pathway and that DKK1 mRNA increased when the WNT signal was activated using Wnt 3a or LiCl (an inhibitor of GSK3β).²⁵ DKK1 has also been observed to be associated with a β-catenin-independent WNT signal in Alzheimer’s disease and tumor models,^26–28 but the mechanism by which DKK1 activates the β-catenin-independent WNT signal is unclear, suggesting that the effects of DKK1 on cellular function are multifaceted and DKK1 signaling in the lung may be highly complex. We expect that future studies will provide more insight into the role of DKK1 in the lungs.

In addition, our included COPD patients differed from controls in terms of age and smoking history, but the results of multiple linear regression analysis confirmed that age and smoking history had no effect on DKK1, and significant correlations were also found between DKK1 and FEV1, FEV1/FVC, and FEV1/Pre after correcting for age, sex, and smoking history.

In in vitro experiments, we found that IL-6, IL-8, and TNF-α increased and DKK1 decreased after airway epithelial cells treated with different concentrations of CSE. After overexpression of DKK1, the level of TNF-α in the cell supernatant was lower than that of the cigarette-induced group, which suggests that the reduction of DKK1 is involved in the regulation of cigarette-induced airway inflammation, and overexpression of DKK1 may be considered as a therapeutic approach to reduce airway inflammation. LRP6 is a receptor for DKK1 and previous studies have identified that the binding of LRP6 to DKK1 is involved in the regulation of inflammation, cell proliferation.^7,29 We found that when DKK1 increased, LRP6 also increased adaptively, suggesting that DKK1 can be involved in subsequent pathway regulation through upregulation and binding to LRP6, but the exact mechanism by which LRP6 is upregulated remains unclear and requires further study.

Previous studies confirmed that andrographolide reduced lung inflammation, Liao W et al found that andrographolide enhanced the anti-inflammatory effects of glucocorticoids in CS-exposed mice,³⁰ Guan SP et al found that andrographolide also exerted antioxidant effects by directly reducing the number of inflammatory cells and enhancing Nrf2 activity in the lungs of CS-exposed mice.³¹ Our study provides a new hypothetical basis for the anti-inflammatory mechanism of andrographolide: andrographolide can ameliorate cigarette-dominated epithelial cell inflammation by upregulating DKK1 and increasing the binding of DKK1 to LRP6.

This study has some limitations, firstly, we combined COPD and AECOP patients in the specific analysis due to the small sample size. Secondly, this study lacks the relevant detection of WNT signaling pathway, and further mechanism research is expected to clarify the relationship between DKK1 and WNT in the pathogenesis of COPD. Moreover, there is no direct evidence that the combination of DKK1 and LRP6. The data in this study provide a new perspective on the anti-airway inflammation mechanism of andrographolide, which requires more in-depth study.

Conclusion

DKK1 is reduced in COPD and positively correlated with lung function, andrographolide and DKK1 can regulate the inflammation of airway epithelial cells induced by cigarette smoke extract by regulating LRP6. This not only indicates that DKK1 may be a biomarker of COPD, but also provides a new perspective on the role of DKK1 in COPD and andrographolide in reducing airway inflammation.

Acknowledgments

This research was funded by 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD18006, ZYJC18012), National Natural Science Foundation of China (31871157, 81830001), and Sichuan Key Research and Development Program(2019YFS0232).

Disclosure

The authors report no conflicts of interest in this work.